Dr. Holly Meany: SABRE Trial - CAR-TA (B7-H3)

Ewing's U
Written By Alana Arens

Dr. Holly Meany (at Children's National Hospital) presents the upcoming SABRE Trial (NCT07172958), a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma and Wilms tumor.

Alana Arens
Next

Dr. David Loeb: A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma